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Abstract
Tissue engineering aims at replacing or regenerating tissues
lost due to diseases or traumas (Langer and Vacanti, 1993).
However, mimicking in vitro the physiological complexity
of vascularized tissue is a major obstacle, which possibly
contributes to impaired healing in vivo. In higher organisms,
native features including the vascular network, the
lymphatic networks and interstitial flow promote both mass
transport and organ development. Attempts to mimic those
features in engineered tissues will lead to more clinically
relevant cell-based therapies. Aside from current strategies
promoting angiogenesis from the host, an alternative
concept termed prevascularization is emerging. It aims at
creating a biological vasculature inside an engineered tissue
prior to implantation. This vasculature can rapidly
anastamose with the host and enhances tissue survival and
differentiation. Interestingly, growing evidence supports a
role of the vasculature in regulating pattern formation and
tissue differentiation. Thus, prevascularized tissues also
benefit from an intrinsic contribution of their vascular
system to their development. From those early attempts
are emerging a body of principles and strategies to grow
and maintain, in vitro, those self-assembled biological
vascular networks. This could lead to the generation of
engineered tissues of more physiologically relevant
complexity and improved regenerative potential.
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Introduction
Tissue engineering applies the principles of engineering
and life sciences toward the development of biological
substitutes that restore, maintain, or improve tissue
function or a whole organ (Langer and Vacanti, 1993).
Today’s successes, in this field, are limited to avascular
(cartilage) or thin tissues (skin, bladder) with slow
metabolism, which rely on either diffusion or quick
angiogenesis due to an inflammatory wound-healing
response. Engineering more complex tissues necessitate
growing a vasculature that promotes cell survival, tissue
organization and rapid vascularization following
implantation.
In the adult, the vascular system forms an extensive,
highly branched and hierarchically organized network. It
is a major regulator of homeostasis through the mass
transport of gas, liquids, nutrients, cells, signalling
molecules and waste products. Besides this classical well-
known function, roles of the vascular system in short-
and long-range communication between organs and in
tissue differentiation have been proposed and are still
debated. Interesting reports suggest that, following trauma
and in response to tissue ischemia and cytokines, bone
marrow derived stem or progenitor cells are recruited to
the circulation (Asahara et al., 1997). Increasing evidence
show they may, then, contribute to vascular healing and
pathologic postnatal neoangiogenesis (Asahara et al.,
1999a; Asahara et al., 1999b; Crosby et al., 2000; Lyden
et al., 2001; Heissig et al., 2002; Edelberg et al., 2002;
Urbich et al., 2003; Bailey et al., 2004; Shi et al., 1998;
Gill et al., 2001; Rajantie et al., 2007). In recent years,
clues accumulated to describe a role of the vasculature in
the development or healing of tissues. Roles in the
maturation of the myocardium (Stainier et al., 1995;
Kramer et al., 1996; Meyer et al., 1995) or in bone
development and healing (Carano and Filvaroff, 2003)
are relevant of this wider, intrinsic, utility. Those still
controversial early studies (Rajantie et al., 2007; Wagers
et al., 2002; De Palma et al., 2003; Voswinckel et al.,
2003; Ziegelhoeffer et al., 2004; He et al., 2004), reveal
multiple functions of the vascular system (Red-Horse et
al., 2007). They more generally depict the important place
of the vascular system in homeostasis and in tissue repair
and, thus, emphasize its potential contribution to engineer
and regenerate complex tissues.
Physiological and Pathological Aspects of the
Vascular System
During embryonic development, morphogenesis of the
vascular system occurs by vasculogenesis (de novo
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formation of blood vessels). The first arrangement is
believed to be blood islands formed by angioblasts that
fuse and sprout to form a primary plexus (Drake et al.,
1998). The vasculature then expands by both
vasculogenesis and angiogenesis. Vasculogenesis was
historically believed to take place only during embryonic
development. It was proven in 1997 that vasculogenesis
also occurs during adult life and is involved in remodelling
the vascular tree (Asahara et al., 1999a; Asahara et al.,
1999b). Angiogenesis is the sprouting, bridging or
intussusceptive growth of existing vessels. All vessels are
formed by endothelial cells (EC), extracellular matrix
(ECM) and mural cells (MC). More complex structures
can also include fibroblasts. The EC create an active non-
thrombogenic, permeable layer in contact with blood.
Endothelial tubes are stabilized by MC (either pericytes
for capillaries or vascular smooth muscle cells for bigger
vessels). A basement membrane (ECM) and elastic laminae
(arterioles and venules) is embedding the two cell types.
Recent efforts led to important discoveries on the molecular
regulation of blood capillary formation. Two excellent
reviews provide extended information on this subject (Jain,
2003; Adams and Alitalo, 2007). Studies on knock-out
mice are an interesting starting point and provide some
insight into this molecular regulation (see Table 1). These
studies emphasize that vascularization involves a complex
spatio-temporal regulation through several molecules
providing a balance between the activation of endothelial
cells to expand or replace the vasculature and the
interaction of endothelial cells with mural cells to ensure
a stable, functional vasculature. The sequence of events
during adult angiogenesis includes the vasodilatation of
the parental vessel, the degradation of the basement
membrane through movements of endothelial cells (EC)
and action of proteolytic enzymes, the migration and
proliferation of endothelial cells to form a cord-like
structure mainly under the control of different VEGF
isoforms and bFGF, the formation of lumen and tube-like
structures under the control of at least angiopoietins 1 and
2, and the stabilization of the capillaries by recruitment of
mural cells under the control of at least TGFβ1 and PDGF-
BB (Hirschi et al., 2002). This layer of MC promotes
stability and functionality of vessels. It synthesizes a
basement membrane and stabilizes the structure. MC
secrete VEGF as a survival factor for the endothelium (Jain,
2003; Reinmuth et al., 2001) and finally MC regulate
perfusion through vasomotion making vessels less prone
to regression (Hellstrom et al., 2001; Koike et al., 2004).
The vascular network is hierarchically structured such that
arterial vessels typically exposed to high pressure and flow
and adapted for mass transport are branching into arterioles
and capillaries. Capillaries are embedding tissues and
represent the most abundant network in the body. Due to
the structure of capillary walls, they are the main site of
gas and nutrient exchange. Capillaries are highly
heterogeneous and are present in very different tissue-
specific forms and functions (Conway and Carmeliet,
2004; Armulik et al., 2005). Following the exchange of
nutrient and waste with the target tissue, capillaries
converge into venules and veins exposed to lower pressure
and characterized by larger lumen and specific structures
(i.e., valves). Interestingly, the vascular system has a low
turnover rate but is very responsive and adaptive to stimuli.
Endothelial cells divide approximately every 3 years and,
in cases such as retinal vessels, every 14 years (Polverini
et al., 2002). The vascular system mostly remains in a
quiescent or very steadily changing state; however few
cases, either chronic or pathologic, entail remodelling
processes: (i) in the female reproduction cycle, massive
angiogenesis occurs every 28 days to prepare a highly
vascularized endometrium as a niche for fertilized eggs;
(ii) in cancer, impaired angiogenesis constantly occurs at
tumour sites where immature vessels are selectively
obliterated as a consequence of VEGF withdrawal
(Benjamin et al., 1999). Besides a normal steady turn-over,
rapid remodelling happens at critical sites such as tumours
or wound healing sites, which are of particular scientific
interest to understand mechanisms of vessels formation
and regression.
A deregulation of the well-balanced growth, resorption
or turn-over of the vascular system is implicated in an ever-
growing list of pathologies (70 examples reported by
Carmeliet, 2005; Carmeliet and Jain, 2000). Typical
examples involve abnormal/excessive angiogenesis or
insufficient angiogenesis and vessel regression. Diabetic
retinopathy and retinopathy of prematurity is due to
impaired leaky vessels that are prone to haemorrhage
(Campochiaro, 2004). Reduced angiogenesis aggravates
Knock-out gene Lethality Vessel phenotype Reference 
VEGF-A Embryonic lethal on E10.5 VEGF+/- and VEGF+/+ phenotypes present disruption, but no abolition, of 
blood island differentiation; impaired lumen formation and vessel organization 
Carmeliet et al., 1996; Ferrara et al., 
1996 
VEGF-B Alive Disruption of the atrial conduction. Hearts with reduced size and vascular 
dysfunction, impaired recovery 
Aase et al., 2001 
Bellomo et al., 2000 
VEGFR1 Embryonic lethal on E8.5 Correct differentiation of EC but impaired assembly Fong et al., 1995 
VEGFR2 Embryonic lethal on E8.5 Defect in the development of haematopoietic and endothelial cells. Absence of 
blood island and reduced haematopoietic precursors 
Shalaby et al., 1995 
VEGFR3 Embryonic lethal on E9.5 Defective blood vessel development, large vessels with abnormal organization 
and defective lumens 
Dumont et al., 1998 
Ang1 Embryonic lethal on E10.5 Lack of vessel remodeling, dilated vessel Suri et al., 1996 
Tie2 Embryonic lethal Lack of vessel remodelling Sato et al., 1995 
Ang2 overexpression Embryonic lethal Disrupts blood vessel formation Maisonpierre et al., 1997 
PDGF-B or PDGFβR Embryonic lethal at E17.5 or 
death at birth 
Hemorrhagic phenotype due to a lack of Stabilization of the vessels by MC Leveen et al., 1994; Lindahl et al., 
1997; Soriano, 1994 
TGFβ1,  50% embryonic death in TGF 
beta 1-/- 
Impaired EC differentiation due to inadequate capillary tube formation, and 
weak vessels with reduced cellular adhesiveness 
Dickson et al., 1995 
TGFβR2   Embryonic lethal on E10.5  Defects in the yolk sac hematopoiesis and vasculogenesis,   Oshima et al., 1996 
Endoglin  Embryonic lethal on E11.5 Poor vascular smooth muscle development and arrested endothelial remodeling Li et al., 1999 
α5β1 integrins and fibronectin   Distended blood vessels, reduced blood vessel pattern complexity Francis et al., 2002 
 
Table 1: Phenotype of some knock-out mice
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ischemic heart disease and results in impaired regeneration
(Jesmin et al., 2005; Shiojima et al., 2005). Osteoporosis
is partly due to low VEGF (Pufe et al., 2003) and to age-
dependent decline of VEGF-driven angiogenesis (Martinez
et al., 2002). Impaired bone fracture healing and bone
formation is partly due to angiogenesis inhibitors that
prevent fracture healing (Yin et al., 2002) or insufficient
angiogenesis (Hausman et al., 2001; Carmeliet and Jain,
2000). The connections between angiogenesis and diseases
along with the cellular and molecular regulation of capillary
formation and remodelling are currently under intense
investigations. However, the formation of mature and
functional capillaries in the context of the structural and
mechanical complexity of tissues remains partly unknown.
There is, for instance, a great challenge in depicting the
cells and their molecular and mechanical interplay resulting
in the vascular tissue pattern formation on large scale (mm
scale) and its effect on the organization of surrounding
tissues. This interest is driven by the possibility to built, in
vitro, relevant models of a vascularized tissue for
therapeutic drug testing but also in tissue engineering and
tissue regeneration to vascularize implants and thus
enhance the success of grafting. Judah Folkman posed the
question whether angiogenesis could be an “organizing
principle in biology and medicine” (Folkman, 2007) and
this is under particular investigation in the attempt to
vascularize engineered tissues in vitro.
Nutrient Limitation
Nutrient limitation is a classical issue in the field of tissue
and organ transplantation. It received wide attention of
scientists and clinicians following the work of Folkman
(Folkman, 1971) on the “dormant diameter” of in vitro
tumour cultures. Folkman suggested that tumours could
not exceed a critical size, without connection to the vascular
system, due to limited diffusion. Actually in 1961, Greene
demonstrated this point by showing that the implanted
tumour re-grew after being switched into a richer
environment (Greene, 1961). Following these studies,
more and more researches revealed that the nutritional
problems are not limited to tumours, but play a role in the
transplantation of many tissues and organs. Physiological
studies show that capillaries are spaced by 200 µm
maximum thus suggesting a range for diffusion in vivo
(Colton, 1995; Moldovan, 2005). Tissues need newly
formed blood vessels or capillaries to pass through it for
the delivery of nutrients.
Nutrient limitations also apply to cell-based tissue
engineering. When the task in this field moves “from lab
bench to the clinic”, a new challenge appears due to the
clinical relevant size of the tailored tissue. In order to get
thick tissue, more living cells should be used. From above,
it is already known that cell survival upon implantation in
vivo is one of the limiting factors for tissue regeneration.
So far, there are already several engineered-substitutes
applied clinically, such as skin, cartilage, and large-scale
vasculature (Brittberg et al., 1994; Kirsner et al., 1998;
Shin’oka et al., 2001). But in other disciplines, like bone,
muscle, myocardium etc, the application is limited and the
amount of tissue formed is small due to central necrosis,
which is at least partly due to a lack of cell survival (Kruyt
et al., 2004; Ishaug-Riley et al., 1998; Suzuki et al., 1998;
Griffith et al., 2005).
When cells are implanted in vivo, nutrition support
comes from the adjacent host blood vessels. For big grafts
(more than several hundreds of millimeters), the constructs
need their own blood vessels and capillaries to provide
nutrition and waste transport to and from the tissue. After
implantation, blood vessels from the host will invade the
implant. However, it takes days to develop the new
vasculature network in the graft from host blood vessels
(Griffith and Naughton, 2002), which means that during
this reconstructive period, the cells far from the host
capillaries experience nutrient limitations, which can result
in cell death. When the graft has been vascularized, the
cells that survived can proliferate and expand again.
Therefore, the formation of new blood vessels, or
vascularization, is an important issue in tissue engineering
(Mooney and Mikos, 1999; Tsai et al., 2003).
Hypoxia
Among the limiting factors, oxygen consumption is high,
whereas the availability of other nutrients, like glucose
and amino acids, is comparatively better than that of
oxygen. It is widely accepted that oxygen is a limiting
factor in cell survival in most grafts. (Muschler et al, 2004).
In cardiac tissue engineering, heart cells critically demand
oxygen supply, and the thickness of tissue formed critically
corresponded to the oxygen diffusion (Carrier et al., 1999,
2002; Lewis et al., 2005; Papadaki et al., 2001; Radisic et
al., 2004a b, 2006). Interestingly, hypoxia-derived
elements stabilize VEGF mRNA and increase VEGF
mRNA transcription, thus acting as an indirect stimulator
for the angiogenesis/vasculogenesis in vivo (Levy et al.,
1996; Shima et al., 1995; Stein et al., 1995; Shweiki, 1992).
Recently, Hung et al. demonstrated that short-time hypoxia
(1% O2) treatment of hMSCs enhanced their engraftment
in vivo (Hung et al., 2007), suggesting that short-term
exposure to hypoxia before transplantation might be a
simple way to improve the transplant survival.
Growing Vasculatures in Engineered Tissues
Engineering complex tissues requires, among other things,
a hierarchical vascular network inducing rapid and stable
perfusion of the implant. This is a current limitation in
engineering tissues of clinically relevant size and
complexity. In addition to mass transport properties, clues
are accumulating to depict an intrinsic role of the vascular
system in the regulation of tissue formation and tissue
differentiation (Lammert et al., 2001; Beaudry et al., 2007;
Maes et al, 2004; Hausman and Rinker, 2004; Mori et al.,
1998). In a more general way, the penetration of vessels
into a tissue allows the transport of molecules or cells (i.e.
macrophages or EPC) regulating, for instance, wound
healing or tissue survival. This makes the vascular system,
intrinsically or not, a crucial player in the normal
development of a tissue. Ideally, the vascularization of in
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vitro-generated implants should follow a hierarchical
network and include consecutively a vessel allowing
microsurgical connection to the host vasculature (~1 mm
diameter) linked to smaller branches mimicking arterioles
or venules (80 to 100 µm) and leading to a capillary tree
(10 to 15 µm) embedded in the tissue. Typically, the main
vessels can be constructed using classical tissue
engineering approaches by building multiple layered tubes
of synthetic and biological material (Kannan et al., 2005;
L’Heureux et al., 2006) and lately, two studies investigated
the fabrication of intermediate sizes (50-150 µm) vessels
with new approaches (Chrobak et al., 2006; Ko and Iwata,
2001). These smaller structures (arterioles and capillaries)
however are, until now, too small to be fabricated and need
to be generated by self-assembly and self-organization of
multicellular systems. Two strategies are developed to grow
capillaries in an implant: (i) by promoting invasion of
vessels from the host by combining the implant with tools
including drug release, functionalized matrices or by
surgical techniques or (ii) by forming, de novo, a vascular
network in the construct before implantation. This is
achieved by orchestrating the proper cascade of events in
vitro. This field of investigation is very active to develop
tissue constructs with engineered capillary networks, which
promotes a more rapid perfusion and improved survival
and differentiation of the associated tissue. There is,
therefore, an important interest in further development of
those self-assembled prevascularized tissues. Below, we
will briefly describe general strategies and requirements
to promote vascularization of tissue engineered constructs
through angiogenesis. We will then depict studies relating
the generation of a capillary bed by vasculogenesis, in
different in vitro-generated tissues.
Current Technological or Surgical Approaches:
Promoting Angiogenesis
Depicting the natural assembly of a vascular system
emphasizes the importance of a tight spatial and temporal
orchestration of the cells and molecules involved. New
vessels must undergo different stages of assembly,
maturation and remodelling before becoming stable and
functional. This can be achieved by promoting invasion
and sprouting of the host vasculature into the implant
through angiogenesis.
Drug Delivery
Drug delivery is an attractive way to promote angiogenesis.
Technologies for the sustained and localized release of
molecules were developed through, for instance, the
encapsulation of molecules in synthetic polymers (Murphy
et al., 2000). Interestingly, therapeutic angiogenesis assays
using gene delivery demonstrated that a single factor might
not be sufficient to form mature functional vessels (Losordo
et al, 2002; Isner et al., 1996). It is essential to promote at
least part of the subsequent stages of remodelling,
beginning with the stabilization of the vessel with MC.
Thus, a cocktail of mitotic and differentiating agents that
is properly delivered is critical. Controlling the dose, rate
and presentation of those factors is a huge challenge and
this necessity led to important technological developments
such as dual factor release systems (Richardson et al.,
2001). The slow release of two factors over different time
period promoted angiogenesis through the sprouting of
local vessels (first step under the control of VEGF) and
their stabilization by recruited pericytes (second step under
the control of PDGF-BB) (Richardson et al., 2001). The
infiltration of the host vessels is strong and the vessels are
mature, but vascularization is still gradual and relatively
slow (more than 2 weeks). Another technological approach
is the development of artificial functionalized ECM
networks. Biomaterials have been developed which bind
molecules using the natural affinity of certain growth
factors for heparin or fibrin. This allows a cell-based release
of molecules and a remodelling of the ECM coupled to
the morphogenetic process. It was proven efficient to guide
the sprouting of endothelial cells (Lutolf et al., 2003).
Interestingly, those strategies could lead to applications
for the vascular system at both macroscale to prevent
restenosis after stent implantation and at microscale to
promote the recruitment of microvessels into areas lacking
a vasculature. However, finding the minimum number of
factors promoting angiogenesis of mature vessels and the
adequate spatio-temporal delivery remain a major hurdle.
The use of direct factors, besides the lack of precise dosage
and pattern of presentation is also limited by a quick
degradation and instability of the factors involved. Patricia
D’Amore (Darland et al., 2001, Ding et al., 2004)
hypothesized that the presentation of the molecules and
creation of microgradients are involved in the recruitment
of mural cells. This emphasizes the importance of cell-
cell cross-talk to release the proper quantities in the proper
ways (including feed-back loops). One possibility is to
target indirectly the angiogenic cascade by triggering genes
upstream. This can be achieved using transcription factors
or indirect growth factors which play a role more upstream
in the hierarchy of the angiogenic process and thus
resulting in the over expression of several growth factors
involved in the morphogenesis process. An interesting
indirect candidate is the pleiotropic factor HIF-1alpha,
which up-regulates VEGF, Ang2, PDGF-BB (Carmeliet
and Jain, 2000) and promotes increased angiogenesis as
shown by angiography and increased blood flow (Vincent
et al., 2000). A limit resides in the fact that this endogenous
molecule is “tightly regulated by ubiquitination and
consequent degradation” (Blau and Banfi, 2001) making
it a difficult candidate to work with. Strategies to inhibit
its degradation by addition of the PR39 (a peptide, which
is naturally produced by macrophages) proved to increase
blood flow (Li et al., 2000).
Surgical Technique
In 1969, Buncke and McLean performed the first
microvascular tissue transplant, which started the surgical
concept named “flap”, which consists of wrapping an
implant with a vascularized transplant (McDowell, 1978).
This technique promoted vascularization of the wrapped
tissue and has been applied to diverse tissues regenerations.
(Khouri et al., 1991; Morrison et al., 1990; Terheyden et
al., 2001; Terheyden et al., 2004). A clinical study depicting
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the replacement of a mandibular defect in a man
successfully used a bone-muscle flap (Warnke et al., 2004).
Based on this mechanism, Erol and Spira developed the
possibility to grow tissues in vivo around an arterio-venous
loop (AV loop) by using artery or vein grafts in a rat model
(Erol and Spira, 1979). Morrison et al. further developed
the concept by combining the AV-loop with polymer
matrices and showed enhanced vascularization of the
implant (Hofer et al., 2003; Cassell et al., 2001). By
implanting the construct ectopically in a highly
vascularized region, the AV-loop promoted vessels
ingrowth and led to an in vivo prevascularized tissue
engineering implant supporting the survival and
differentiation of cells (Messina et al, 2005; Bach et al.,
2006). This technique was clinically applied to skin tissue
engineering (Tanaka et al., 1996, 2000, 2006) and, in
combination with hard porous matrices, promoted the
survival of transplanted osteoblasts (Kneser et al., 2006
a,b,c).
First Attempts of In Vitro Prevascularization:
Promote Vasculogenesis and Angiogenesis
An alternative concept termed prevascularization is rooted
in a large body of research on in vitro angiogenesis and
aims at creating a vasculature, de novo, from its individual
components.
Prevascularization of a tissue consists of promoting
the formation of a vascular network inside an engineered
tissue, prior to implantation. This can be achieved by
culturing, in vitro, relevant cell types (i.e., EC, MC and
tissue-related cell types) and recapitulating some
developmental processes typical of vasculogenesis.
Prevascularization is, among others, dependent on the EC/
MC source and their phenotypic stability, the EC/MC
interaction with the tissue-related cell types, the stability
of the neovascular structures and the interaction with the
biomaterial. The aim is to combine the implant with a
functional vascular network prior to implantation to
promote survival, differentiation and integration of the
engineered tissue or as an intermediate form playing a role
to accelerate regeneration of the final tissue. Below, we
will discuss the current status of prevascularisation in
different tissues.
Skin
The in vitro formation of microvessels within an
engineered tissue was, to our knowledge, first described
by Black et al. (1998). A skin equivalent was fabricated
by co-culturing dermal fibroblasts, keratinocytes and
human umbilical vein endothelial cells (hUVEC) on
chitosan/collagen scaffolds. A tubular network formed by
self-organization of EC in cooperation with fibroblasts. It
included lumen with typical intercellular junctions, Weibel-
Palade bodies in EC and a basement membrane of laminin
and collagen IV. The skin tissue self-organized into strata
with a pseudo-basal layer, stratum spinosum and stratum
granulosum (Black et al., 1998). In a similar engineered
skin construct (Tremblay et al., 2005), the presence of
microvessels accelerated the implant’s perfusion in vivo
(4 vs. 4-14 days). Interestingly, the perfusion was as fast
as for a full human skin transplant. The stabilization of the
vessels by MC wasn’t investigated but the number of
vessels did not significantly decrease after 14 days
indicating that the vessels are stable over time. A third
study by Shepherd et al. (2006) was performed using
human endothelial progenitor cell-derived EC from
umbilical cord blood, EPCs from adult peripheral blood
(habEPC-EC) or hUVEC (Benjamin et al., 1999).
Keratinocytes were first cultured in a decellularized human
dermis. The endothelial cells were then seeded on the deep
surface of the graft. Microvessels formed and underwent
maturation and stabilization by MC derived from SMC
(Schechner et al., 2000; Yang et al., 2001). No in vitro
data could assess the functionality of the construct
(Shepherd et al., 2006).
Bone
The interaction between bone and the vascular system is
well described (Carano and Filvaroff, 2003) and of
particular interest for bone prevascularization. Reciprocal
interactions between bone and vascular-related cells
includes the production of BMP2, endothelin-1 and insulin-
like growth factor by EC (Bouletreau et al., 2002; von
Schroeder et al., 2003; Villars et al., 2000) and the
production of VEGF by osteoblasts with an effect on EC
survival, proliferation and differentiation/organization in
vitro (Deckers et al., 2000; Furumatsu et al., 2003; Kaigler
et al., 2003; Stahl et al., 2004; Wenger et al., 2004; Wang
et al., 2004).  Interestingly, direct contact (EC/osteoblast)
may be essential to form capillary-like structures in 2D
and in 3D (Unger et al., 2007; Stahl et al., 2004; Wenger
et al., 2004). We demonstrated the possibility to form, in
vitro, a prevascular network of cord-like structures in a
spherical model of human mesenchymal stem cells (hMSC)
and hUVEC. The addition of MC precursors in the form
of mouse embryonic fibroblast did not trigger the
maturation and stabilization of the network (as compared
to skeletal or cardiac muscle systems, see below). Although
primitive, this network further maturated, formed lumens
in vivo and made connection to the host vasculature after
2 weeks (Figure 4). The interaction of hMSCs with
hUVECs, in this system, induced an upregulation of the
osteogenic marker alkaline phosphatase suggesting an
improved differentiation of the osteoprogenitors
(Rouwkema et al., 2006). Elaborating on the work
described above, we are currently building models of
multicellular spheroids to study vasculogenesis (Figure 1-
3). Multiple layer spheroids of different cell types can be
built by sequential addition in a hanging drop. Those
multicellular spheroids can be used as models to study
cell-cell interactions. Unger et al. tested the potential of
several biomaterials (porous hydroxyapatite, porous
calcium phosphate, porous nickel-titanium and silk fibrin
nets) to support vasculogenesis in vitro. Microvessels
didn’t form when EC (human dermal microvascular
endothelial cells, hDMEC) where seeded alone on
biomaterials. In co-culture with human osteoblasts (HOC)
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or with the human osteoblast cell line MG-63, hDMEC
formed extensive tubular networks among osteoblasts cells.
This suggests that signals from osteoblasts were essential
for the formation of those structures and the survival of
hDMEC. Interestingly, the addition of angiogenic factors
failed to replace the role of osteoblasts. The adequate
presentation, distribution and the proper dosage of factors
(cell-cell interaction, soluble factors or cell-ECM
interaction) leading to EC organization could only be
recapitulated by co-culture with osteoblasts. In both
studies, the stabilization of the microvessels was not
achieved prior to implantation (Unger et al., 2007).
Skeletal Muscle
A keynote paper by Levenberg et al. (2005) showed the
possibility to prevascularize skeletal muscle tissue using
endothelial, fibroblast and myoblast cells. EC (hUVEC or
human embryonic stem cells derived endothelial cells
(hESC-EC)) formed microvessels including lumens in
vitro. They were further stabilized in a process mediated
by mouse embryonic fibroblasts (mEF). mEFs were
recruited around the vascular structures and differentiated
into smooth muscle actin-positive mural cells. Their
presence increased the local level of VEGF, consistently
with in vitro (Darland et al., 2001) and in vivo (Hellstrom
et al., 2001; Koike et al., 2004) studies. This adds a
substantial clue to the role of MC in the survival and
stabilization of vascular structures. A fraction of the mouse
skeletal myoblasts cells (C2C12) differentiated into
aligned, elongated multinucleated cells similar to muscle
fibres. In vivo, the prevascular network anastamosed to
the host vasculature within 14 days after subcutaneous,
intramuscular or anterior abdominal wall implantation in
SCID mice. A precise study of the in vivo performance of
the construct proved that prevascularization improved the
vascularization, blood perfusion and survival of the
engineered tissue (Levenberg et al., 2005).
Figure 1: Multicellular spherical system can be grown
in drops hanging (blue arrow) from a deep 96 well-
plates. Half a million hMSC aggregates at the air-liquid
interface (left picture, red arrow).
Figure 2: Self assembly of cells at the air-liquid
microscope viewed using an inverted microscope after
24 hours. Scale bar: 100 µm.
Figure 3:  The Sequential addition of hMSC and
hUVEC (prelabeled with CFSE, in yellow) lead to
multiple layered microtissues. A typical sprouting of
precapillary structures appears after five days at the
interface between the two populations. All nucleus are
stained in blue (DAPI) and red is the endothelial marker
cd31.  Scale bar: 100 µm.
Figure 4: A view of the external part of the scaffold
implant. Note the overlapping of the CD31+ structures
(in red) and the lectin (in green) demonstrating the
anastomosis of the engineered vessels with the host’s
vasculature. Scale bar: 100 µm.
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Vasa Vasorum
Wu et al. described a construct using smooth muscle cells
and endothelial cells on a porous PGA-PLLA scaffold. A
potential application is to fabricate a prevascularized patch
as a vasa vasorum for the thick-walled arterial conduit of
heart valves. Human SMCs were cultured for 6 days in a
PGA/PLLA scaffold before adding, on top of the construct,
a layer of human endothelial progenitor cells isolated from
cord blood (hcbEPC-EC). The EC invaded the tissue of
SMC, assembled into capillary-like structures which were
stabilized by mural cells derived from SMC. The
interaction of the EC with SMC was essential for EC
survival and assembly into microvessels. This study was
the first to first described the possibility to use hcbEPC-
EC as a clinically relevant source of EC for
prevascularizing implants (Wu et al., 2003).
Cardiac Muscle
Caspi et al. designed a muscle construct of cardiomyocytes,
EC and fibroblasts for application as a cardiac muscle
patch. Cardiomyocytes and EC were human embryonic
stem cell-derived (hESC-CM and hESC-EC); fibroblasts
were mouse embryonic stem cells (mEF). hUVEC were
used as a reference.  The co-culture of CM and EC did not
lead to organization of EC. Only the tri-culture including
the fibroblasts resulted in highly vascularized constructs
with capillaries stabilized by mural cells derived from the
fibroblasts. Interestingly, the cooperation between the
different cell types was accentuated since (i) the fibroblast
supported the organization of ECs (EC proliferation, EC
density (number and area density of lumen) and (ii) CM
proliferation and differentiation markers were increased
by the presence of the other cell types (Caspi et al., 2007).
Another interesting study by Kelm et al. depicts the
construction of macrotissues using multicellular spheroids
as building blocks. Spheroids including human
myofibroblasts (hMF) and hUVEC formed primitive
vascular structures in vitro. The macrotissues, including
or not, this primitive network, were grafted and cultured
on top of a chicken embryo’s chorioallantoic membrane.
Noteworthy, the vasculature of the prevascularized
macrotissue developed connections (although limited) with
the host as shown by the presence of erythrocytes and
improved the graft integration compare to a non-
prevascularized macrotissue (rejection, scar tissue, lack
of vascularity). A lower expression of VEGF in the
prevascularized construct was described as a sign of better
oxygenation of the construct (Kelm et al., 2006).
Constructs with Intrinsic Vascularization Potential
Two studies described the possibility to engineer constructs
using biopsies with heterogeneous cell populations
including at least an endothelial type and a tissue-related
type. Zimmermann et al. demonstrated the possibility to
engineer a cardiac muscle with capillary structures from a
cardiac neonatal rat biopsy including various cell types.
The biopsy was mixed with collagen type I and matrix
factors, shaped into a ring and conditioned by mechanical
stretching. CD31+ (a platelet and endothelial cell adhesion
molecule) vessel-like structures were observed in the tissue
in vitro, demonstrating the possibility to grow capillaries
in complex tissue directly using a heterogeneous biopsy
(Zimmermann et al., 2002). Scherberich et al. presented a
bone tissue-engineered construct with vasculogenic
potential starting from the heterogeneous stromal vascular
fraction of human adipose tissue. The mononuclear fraction
of biopsies including mesenchymal progenitors and an
endothelial cell type were seeded on porous hydroxyapatite
scaffolds and preconditioned in a bioreactor. Interestingly,
results show that a fraction of the implanted cells (possibly
the CD31+ population) participated, after implantation, in
the formation of a vasculature and possibly facilitated or
extended the invasion of blood vessels from the host
(Scherberich et al., 2007).
Lessons from Those Early Attempts: Emerging
Principles and Shared Strategies
The prevascularization of tissues is a step forward in
generating more complex tissues mimicking native tissue
physiology or physiopathologies. Combining the
engineered tissue with an intrinsic vascular system
promotes a rapid perfusion of the implant, independently
from its thickness. It proved, in defined systems, to enhance
its perfusion, survival and differentiation of the tissue. Of
special interest for tissue engineering are the mechanisms
underlying the interaction of the endothelium with its
microenvironment and the regulation of organ
development and pattern formation (Red-Horse et al.,
2007). ECs are a source of survival and differentiation
factors that could play a role in in vitro preconditioning of
the tissue. EC produce pro-inflammatory factors (Peters,
2003) taking part, in vivo, in the inflammatory response.
Noteworthy, those early works reveal the prime importance
of the tissue-related cell types in the formation of
microvessels: (i) a close collaboration between the tissue
cell types and the vessel cell types is essential. (ii) The
tissue-related cell type is a potential “factory” of signals
thus avoiding the addition of molecules (Levenberg et al.,
2005; Unger et al., 2007). The prevascularization of a tissue
often takes place in the microenvironment (i.e. culture
medium) of the tissue involved and the addition of direct
angiogenic factors does not improve the capillary
formation (Levenberg et al., 2005; Unger et al., 2007).
Furthermore, an inadequate exposition to angiogenic
factors like VEGF over a long period may results in
deformed, non-functional blood vessels (Springer et al.,
1998; Pola et al., 2001). This stresses the role of the tissue-
related cell type to create a microenvironment with
adequate presentation, distribution and dosage of
molecules and the importance of direct heterotypic
interaction. Promoting interaction between the cell types
involved using up-stream mediators (HIF-1alpha is a
classical target) or indirect factors may push the tissue itself
to produce the proper microenvironment for vascular
organization and stabilization. Signals between the vascular
cells and the tissue-related cells mostly remain to be
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assessed and might include the production of direct or
indirect factors, direct cell-cell interactions, matrix
production as a bed for EC sprouting and the generation
of forces on a large-scale.
Vessel Maturation Is Essential
A current limitation of the prevascularization concept
resides in the in vitro maturation and stabilization of the
vasculature. Both in vivo and in vitro, clues accumulate
indicating that immature microvessels have (i) a limited
potential to anastamose to the host vasculature (Rouwkema
et al., 2006) (Figure 5) and (ii) are prone to regression
(Koike et al., 2004). Physiological observation of immature
vascular network shows they are more fragile, leaky, close
to some pathological conditions (Benjamin et al., 1999;
Hellstrom et al., 2001; Lindahl et al., 1997) and can lead,
after implantation, to the formation of oedema (Jain, 2003;
Lindahl et al., 1997). In a study by Nör et al., one capillary
on five, produced in vitro, was perfused in vivo and non-
functional capillary-like structures regressed and finally
disappeared within 21 days. Current knowledge suggests
that networks must be in a mature stage prior to
implantation or rapidly go through remodelling processes
in vitro to become mature and functional in vivo. It implies
the addition of MC, MC precursors or the differentiation
of tissue-related cell types into MC. MC which are
recruited by the EC through TGFβ and PDGF signaling
play a role in stabilization by producing ECM to provide
structural integrity and by secreting survival factors to
inhibit apoptosis of endothelial cells (Levenberg et al.,
2005; Ramsauer et al., 2007). They are directly
contributing to EC organization (Kunz-Schughart et al.,
2006; Darland et al., 2003; Caspi et al., 2007). The
pericyte-to-endothelial cell ratio can vary from 1:100 in
skeletal muscle to 1:1 in the retina (Armulik et al., 2007):
this reflects the heterogeneity of the phenotype of vessels
and illustrates the complexity of the in vitro organ-
dependent maturation of the vasculature. Interestingly;
those early works bring new insights into basic questions
in vascular biology: the recruitment of MC proved to
induce, in classical vascular biology models, an important
decrease in EC proliferation (Antonelli-Orlidge et al.,
1989). In their study, Caspi et al. (2007), however, showed
that, in a more complex system including a surrounding
tissue, the addition of MEF increased proliferation of EC
and stabilized vessels.
Concluding Remarks and Perspectives
From those early – proof of concept – works emerged
paradigms on the large scale organization of tissues with a
vasculature; the next generation of constructs must prove
additional benefits. The integration to the surrounding
organ, the trophic effect of prevascularization on
surrounding tissue differentiation along with the
remodelling of the vasculature after implantation are of
particular interest. Further organ specific maturation of the
vasculature is essential for physiological function.
Continuous capillaries in muscle, fenestrated capillaries
in kidney or capillaries including tight junctions for
permeability to various molecules at the blood-brain or
blood-retina barrier or responsive to vasoactive stimuli
(arterial-venous system) are typical of a more mature stage.
Prevascularized constructs provide models to uncover links
between tissues through cell cooperation, tissue
differentiation or tissue organization. Mechanical stimuli,
shear stress and interstitial flow are known to enhance the
polarity of endothelial cells and form instructive physical
and biochemical gradients and represent additional stimuli
that must be investigated (Sieminski et al., 2004; Helm et
al., 2005; Inoguchi et al., 2007). Since capillary
morphogenesis results from a combination of biomolecular
and mechanical clues, those prevascularized constructs
should benefit from the use of, for instance, bioreactor
technology. Finally, prevascularized tissues also provide
an interesting and effective tool to study physiology and
physiopathologies of the vasculature in a more complex
tissue context; that is in a non-endotheliocentric system.
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